Andrew Stephen
Team Lead, Biochemistry & Biophysics Research Team NCI, RAS Initiative
Andy Stephen has over 25 years’ experience in biochemical characterization of molecular interactions. Over the last 13 years his group has focused on KRAS and supported the development of KRAS-G12C, pan-KRAS and KRAS-PI3Ka inhibitors, as part of a collaborative effort between the NCI RAS Initiative and BridgeBio Oncology Therapeutics.
Seminars
Thursday 10th September 2026
From RAS Biochemistry to Drug Design: How Mutant Cycling & GTP Thresholds Inform Next-Generation RAS Inhibitors
1:30 pm
- Revisiting the core biochemistry of RAS mutants to understand how cellular GTP loading and signaling thresholds drive oncogenic transformation
- Examining what first-generation covalent and non-covalent inhibitors revealed about mutant-specific cycling behavior and switch-II pocket accessibility
- Applying biochemical insights from early KRAS inhibitor successes and limitations to guide the design of next-generation RAS-targeted therapies
